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1. Introduction 2. Materials and methods 
Ribonucleotide reductase requires a dithiol as 
hydrogen donor for reduction of ribonucleotides to 
the corresponding deoxyribonucleotides [ 1,2]. Origi- 
nally, thioredoxin, a small dithiol protein, was found 
to be the hydrogen donor in the reaction [I]. The 
oxidized thioredoxin (thioredoxin&) is reduced by 
the specific enzyme NADPH-thioredoxin reductase. 
In [3], another system was found in an Escherichia 
coli mutant lacking detectable thioredoxin. The 
monothiol, glutathione, is hydrogen donor in the pres 
ence of glutaredoxin, a novel small protein that thus 
couples the oxidation of glutathione to the reduction 
of a ribonucleotide [3]. To study the mechanism of 
action of glutaredoxin we have used the glutathione 
analogues l-5 shown below in scheme 1. Our results 
provide evidence for a glutathione-binding site on 
ribonucleotide reductase. 
F$H~ ~NH~:;;B+~~H 
1 ;R'= C,H,CH,OCO-, R" = H 
2;R'= H , R" =-CH&H,pBr 
J;R'= H , R" =-CH,COC,H, 
4 ; R' = H , R"=-CH,COC,\pN, 
2 ; R' = R" q -tOOCH&,H, 
Scheme 1 
+ To whom correspondence should be addressed 
NADPH, CDP, ATP and GSH were obtained from 
Sigma. [3H]CDP was from Amersham. Glutaredoxin 
was prepared from E. coli ClO-17 by an immunoad- 
sorbent technique (in preparation). Ribonucleotide 
reductase from E. coli was a mixture of proteins Bl 
and B2 [I] and was of 95% purity; it was a generous 
gift from Dr B.-M. Sjiiberg, Department of Biochem- 
istry, Karolinska Institute. Glutathione reductase 
(highly purified from yeast) was from Sigma. Bovine 
serum albumin was from British Drug Houses. Thiore- 
doxin [4] and thioredoxin reductase [S] were prepa- 
rations from E. coli B. The glutathione analogues 
2-4 were from previous studies [6]. Derivatives 1 and 
5 were prepared by a modification of the procedure 
in [7] and were found to be pure by thin-layer chro- 
matography and elemental analysis. However, 1 was 
found to oxidize easily and the thiol content had 
dropped to 75% at the time of the experiment. Stock 
solutions of derivatives l-5 were prepared in 
dimethyl sulphoxide. This solvent alone was shown to 
have only small effects in the assay of the activity of 
ribonucleotide reductase; <5% inhibition at 8% DMSO 
(v/v). The’ activity of ribonucleotidereductase in the 
presence of inhibitors of the glutaredoxin system was 
assayed by determining the conversion of [3H]CDP 
to dt3H]CDP as in [8]. Relevant concentrations were: 
E. coli ribonucleotide reductase (subunits Bl t B2) 
0.3 PM; NADPH 1 mM; [3H]CDP 0.5 mM; glutare- 
doxin 0.5 PM, glutathione reductase 8 pg/ml and GSH 
and GSH-analogue concentrations were as indicated. 
In assays of ribonucleotide reductase with the thiore- 
doxin system, GSH and glutathione reductase were 
exchanged for thioredoxin 4 PM, and excess thiore- 
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doxin reductase (15 pg/ml). Incubations were for 
20 min at 37°C in 120 /.d final vol. Assays of thiore- 
doxin in the insulin disulfide reduction system were 
performed as in [9] by following the oxidation of 
NADPH spectrophotometrically. 
3. Results 
In the glutaredoxin assay system, derivatives 1 and 
2 were found to be linearly competitive with glutathi- 
one by both Lineweaver-Burk (l/V0 vs I/S,) and 
Dixon (1 /V, us I,) criteria, the results for 2 being 
depicted in fig.]. The Ki values for 1 and 2 were 
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Fig.1, Lineweaver-Burk (top) and Dixon (bottom) plots of the 
inhibition of glutaredoxindependent ribonucleotide reduc- 
tase by S-Q+bromobenzyl)glutathione (2). Velocity units are 
nmol dCDP formed/20 min. The points are experimental and 
the lines derived by regression analysis of the data assuming 
linear, competitive inhibition with Ki = 0.80 i 0.04 mM. The 
inhibitor concentrations (upper figure) were: (a) 0 mM; 
(b) 0.83 mM; (c) 2.1 mM; (d) 4.2 mM. The GSH concentra- 
tions (lower figure) used were: (e) 1.7 mM; (f) 0.83 mM; 
(g) 0.42 mM; (h) 0.17 mM. 
Table 1 
Inhibition of glutaredoxin- and thioredoxin-dependent 
ribonucleotide reductase by glutathione derivatives 
Derivative Kt (mM) in gluta- 
redoxm system 
Concentration for 50% 
inhibition (Is,,), mM of 
thioredoxin system 
la 0.38 f 0.05 3.5 
2 0.80 * 0.04 b 
3 1.2 + 0.2 1.8 
5 _c 3.0 
a Concentrations of 1 were calculated by weight; the free SH 
titer was found to be 75% of theoretical 
b No inhibition detected 
’ Not calculated 
found to be 0.38 + 0.05 mM and 0.80 ?r 0.04 mM, 
respectively (see table 1) by calculation from the 
mean intersections on the 1 /So axis of the appropriate 
Lineweaver-Burk plots. Compound 3 gave a linear 
Lineweaver-Burk plot with the intersection on the 
l/V, axis constant for various inhibitor levels. How- 
ever, the Dixon replot of these data may indicate a 
slight curvature at lower substrate concentrations ( ee 
fig.2). If a linear competitive model is assumed, the 
Ki for 3 in the glutaredoxin system is 1.2 + 0.2 mM. 
Welldefined, non-linear inhibition behavior (Dixon 
plot) was found for the 4-azido analogue 4, and for 5, 
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Fig.2. Dixon plot for S-(phenacyl)-glutathione inhibition of 
glutaredoxindependent ribonucleotide reductase. Velocity 
units are nmol dCDP formed/20 min. The points are experi- 
mental and the lines are theoretical for linear competitive 
inhibition with Ki = 1.2 f 0.2 mM (obtained from the 
Lineweaver-Burk intersects). The GSH concentrations used 
were: (a) 1.7 mM; (b) 0.83 mM; (c) 0.42 mM; (d) 0.17 mM. 
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blocked on both N and S sites, but these complex 
inhibitors were not investigated further. 
All of the compounds used with the exception of 
2 were inhibitory in the thioredoxin-dependent assay 
of ribonucleotide reductase. The concentrations 
required for 50% inhibition are given in table 1. Inhi- 
bition types were more complex than in the glutare- 
doxin-based system; e.g., that for 3 was noncompeti- 
tive with a Ki of 2 mM. In view of the relatively weak 
inhibitions of the thioredoxin assay system and the 
complex inhibition kinetics observed, this aspect was 
not studied in detail. None of the compounds hown 
in table 1 had any detectable ffect on the insulin- 
reducing activity of thioredoxin. S-Blocked and 
N,S-diblocked glutathione derivatives showed little, if 
any, inhibition of yeast glutathione reductase; in any 
case this enzyme is used in excess in the assay. 
4. Discussion 
From the results obtained with thioredoxin-depen- 
dent ribonucleotide reductase it is clear that GSH ana- 
logues can inhibit, albeit weakly, this activity (table 1). 
The fact that these compounds do not inhibit, to any 
detectable l vel, the insulin disulfide reducing ability 
of thioredoxin argues trongly that there is a GSH- 
analogue binding site on ribonucleotide reductase. 
This in turn implies a GSH-site on that enzyme. In 
this context it should be pointed out that excess GSH 
is not inhibiting ribonucleotide reductase in the pres- 
ence of thioredoxin. It thus seems likely that the bind- 
ing of the GSH analogues to a GSH site on ribonucle- 
otide reductase interacts with the function of the 
active site. 
Interpretation of the results for glutaredoxin- 
dependent ribonucleotide reductase ismore complex. 
There is undoubtedly aGSHsite in this system which 
can be blocked by the derivatives tested. The observa- 
tion of linear competitive inhibition by 1 with a Ki 
fairly close to the Km (0.4 mM) for GSH itself [lo] 
argues that for 1 this site is the active site. Indeed, 
there must be little steric constraint around the thiol 
group of GSH in the active site in view of the large 
p-bromobenzene group. This statement has to be 
qualified because of the difference in inhibitory 
behavior between the S-(phenacyl)-(3) and S-@azido- 
phenacyl)(4)derivatives. It is not possible on the cur- 
rent evidence to decide the location of this GSH-site. 
It may be on the glutaredoxin and/or ribonucleotide 
reductase. It is clear from table 1, comparing results 
for 1 and 3, that these inhibitions involve specific 
interactions and are not the result of random binding 
to ribonucleotide reductase. Thus, in the glutaredoxin 
system 1 is a significantly better inhibitor than 3, but 
the reverse is the case in the thioredoxin system. More 
strikingly, 2 does not inhibit the thioredoxin system, 
detectably, but is a reasonably strong inhibitor for 
the glutaredoxin system. 
GSHderivatives inhibit, in a specific manner, ribo- 
nucleotide reductase from E. coii as assayed by both 
glutaredoxin and thioredoxindependent systems. 
While it is not yet possible to assign the inhibition 
site for the glutaredoxin system, there appears to be 
clear evidence of a GSH-site on ribonucleotide reduc- 
tase when assayed in the presence of the thioredoxin 
system. 
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